Skip to main content

Hypertrophic Cardiomyopathy: Symptoms, Causes, Treatment

اعتلال العضلة القلبية التضخّمي

Quick summary

Hypertrophic cardiomyopathy is abnormal heart-muscle thickening that may impair filling or blood outflow. It often has a genetic basis, ranging from few symptoms to disease requiring specialist treatment and surveillance.

Medical disclaimer: This content is for educational purposes only and is not a substitute for consulting a qualified physician. Do not use this information for self-diagnosis or self-treatment.

What is Hypertrophic Cardiomyopathy?

Outflow obstruction may be present or absent, which changes management. Not every thickened heart has HCM; hypertension and other conditions can also increase wall thickness. Rhythm risk must be assessed individually rather than assumed to be identical in all patients.

Related reading: When should I see a cardiologist?.

Symptoms

Symptoms may include exertional breathlessness or chest pain, palpitations, dizziness or fainting, while some patients remain symptom-free. New or worsening symptoms warrant reassessment. Good exercise performance alone cannot exclude the disease.

Causes

Many cases involve genetic variants affecting heart-muscle proteins. Family history may be unclear, and testing does not identify an explanatory variant in everyone. Clinicians assess alternative causes of thickening before confirming HCM.

Risk factors

An affected relative or relevant genetic variant raises the likelihood of disease, with variable expression even within families. Clinical and imaging findings, fainting history and rhythm abnormalities inform complication risk; wall thickness alone does not determine every decision.

Diagnosis

Assessment includes echocardiography, ECG and family history, sometimes with rhythm monitoring, MRI or tailored exercise testing. Genetic counselling and first-degree-relative screening should be discussed. An inconclusive genetic result does not replace appropriate clinical family surveillance.

Treatment

Medicines such as beta blockers may relieve symptoms and obstruction in suitable patients. Selected cases may need muscle-targeted medicines or septal-reduction procedures at experienced centres. Defibrillator implantation depends on arrhythmic risk, not the diagnosis alone.

Complications

Atrial fibrillation, heart failure and, in higher-risk patients, dangerous arrhythmias can occur. Diagnosis does not mean sudden death is expected in every patient. Prevention relies on repeated risk assessment; atrial fibrillation requires discussion of stroke prevention.

Prevention

Lifestyle cannot prevent inherited HCM, but family detection, management of other illnesses and follow-up help. Light-to-moderate activity benefits many patients; vigorous or competitive sport needs individualized discussion. Avoid both unsupported blanket bans and unplanned intense training.

When to see a doctor

Persistent chest pain, severe breathlessness or fainting, particularly during exertion, requires urgent assessment. Report worsening palpitations or declining exercise tolerance. Tell the team about sudden cardiac death or a similar diagnosis in relatives.

Scientific references

  1. Hypertrophic cardiomyopathy — American Heart Association
  2. 2024 hypertrophic cardiomyopathy guideline: key points — American Heart Association
  3. Cardiomyopathy: diagnosis — NHLBI
  4. Cardiomyopathy: treatment — NHLBI